Contact
Please use this form to send email to PR contact of this press release:
FDA approves osimertinib for locally advanced, unresectable (stage III) non-small cell lung cancer following chemoradiation therapy
TO:
Please use this form to send email to PR contact of this press release:
FDA approves osimertinib for locally advanced, unresectable (stage III) non-small cell lung cancer following chemoradiation therapy
TO: